Novonesis A/S (NSIS-B.CO) Zen Horizon Research Report

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing market, or creating an entirely new one?5/10

  A

  Bottom line: the ceiling is fairly broad, but this is fundamentally about deepening a large market that already exists, not creating a new one from scratch. All of Novonesis’s core businesses — industrial enzymes, probiotics, food enzymes, feed enzymes, and agricultural biologics — are mature categories with 20–40 years of history. Demand has long existed. The company’s role is to use better strains and enzymes to push penetration higher and increase unit value for customers. It is a deepener of existing markets, not a creator of incremental markets. That means its growth is mid-paced compounding in the single digits, not exponential.

  Addressable market size, checked by order of magnitude. The report’s framing is: global industrial enzymes at about USD 9–10B, B2B probiotic formulations at about USD 8–10B, and food functional ingredients at about USD 80–90B, for an aggregate serviceable obtainable market (SOM) of about USD 25–30B. Third-party data is broadly consistent: the global probiotics market is about USD 76.6B in 2025, with a CAGR of about 8.5% through 2030. Note that this includes OTC end markets; Novonesis only captures the upstream B2B strain and formulation layer, roughly one-tenth of that. In other words, the TAM looks large, but the layer Novonesis can actually monetize is the narrow slice of ingredients sold to Nestle, Danone, Henkel, and similar customers. FY2025 revenue was EUR 4.157B (≈ DKK 32,376M, 2025 annual report), already implying fairly high penetration versus SOM. Further expansion depends on the industry itself growing, not on occupying empty space.

  Where incremental growth comes from: making an existing market larger. The real growth drivers are: ① rising meat and aquaculture consumption plus antibiotic substitution driving feed enzymes (the report gives CAGR 9–12%); ② health trends plus emerging-market penetration driving probiotics (CAGR 8–10%, with 2025 emerging-market organic growth of 9%, ahead of 6% in developed markets); ③ agricultural biologics under pressure to reduce pesticide use (CAGR 11–15%). These are all stories where the demand pool already exists and is simply getting larger.

  Only two areas come close to a “new market,” and both are still very small. Biosurfactants / bio-beauty (the report gives CAGR 14–18%) and microbiome interventions have some flavor of creating new categories. Yet the report itself also acknowledges that these two areas are “fast-growing but small-scale, and may only break through the ten billion scale over the next 5–10 years.” Their contribution to group revenue today is negligible and cannot support the group-level narrative.

  The honest Baillie Gifford-style conclusion: Measured against LTGG’s yardstick of “finding great growth stocks that can rise fivefold in ten years,” Novonesis has a ceiling high enough that it will not hit it in two or three years, but it lacks the trait Baillie Gifford values most: defining a genuinely new market with a steeply rising demand curve. It is a mid-speed compounder that is the absolute leader in broad, mature markets. The ceiling offers a long runway, but the snow is not especially deep or especially steep.

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Will growth mainly be driven by volume, price, or new businesses?4/10

  A

  Bottom line: a five-year revenue doubling (CAGR ≥14.9%) is almost impossible; on the current trajectory, revenue is more likely to rise only 35–45%. This is the hardest hurdle in the case and the biggest gap between Novonesis and Baillie Gifford’s “fivefold in ten years” template. Management’s own 2026 guidance is organic growth of +5–7%, with a 5-year long-term target of +6–8%. At the midpoint of +6.5% compounded, revenue after five years would be about 1.37 times today’s level, far short of doubling. A doubling would require five consecutive years of +15% organic growth, something the company or its predecessors (Novozymes/Chr. Hansen, historical CAGR 6–8%) have never delivered.

  Breaking growth into three components: volume leads, price helps modestly, M&A is garnish, and there is no explosive source.

  • Volume is the main engine, but its ceiling is the industry growth rate. The latest data confirms this structure: within Q1 2026 organic growth of 7%, volume contributed 6% and price only 1%. Volume growth essentially follows the growth of subsegments such as feed enzymes, probiotics, and agricultural biologics. A segment CAGR of 8–12% is the upper limit for volume growth; the company does not have a singularity that can double volumes.
  • Price is barely a growth source. Annual price increases of only 1–2 points show pricing power, since switching strains and enzymes is highly costly, but they are not a growth engine. This is very different from consumer businesses whose strong pricing power drives growth through price hikes.
  • New businesses/M&A only add at the margin, and are not a second engine. The EUR 1.5B acquisition of dsm-firmenich’s stake in the feed enzymes alliance closed on 2025-06-02 and contributes only about 3% of group revenue in its first full year (the acquired asset had net sales of about EUR 300M in 2024). This is a one-off buyout of a stake, bringing a distribution right in-house from someone else. It does not open a new growth pole.

  There is also a hidden headwind: FX can shrink “organic growth” into much lower “reported growth.” The key risk highlighted in the report is that most sales are in USD (North America/Latin America/Asia Pacific), while accounts are kept in DKK. When EUR/USD strengthens, +7% organic growth may translate into only +1–2% reported revenue growth. In other words, the revenue growth investors actually see in the accounts is often lower than operating-level organic growth, further reducing the odds of a doubling.

  The honest Baillie Gifford-style conclusion: Novonesis cannot answer the “five-year doubling” question. It is a high-quality but not fast machine that reliably produces single-digit organic growth, driven by volume and supplemented by price and M&A. For growth investors seeking exponential revenue expansion, this is a structural miss. One should not assume a sudden acceleration simply to fit a growth narrative.

  Jun 10, 2026
• QAfter five years, what will take over as the next growth engine? Does this “second curve” exist today?4/10

  A

  Bottom line: Novonesis does not have a clear second curve that can “take over as the main engine” five years from now. It looks more like several branches of the same curve moving slowly upward at the same time, not a relay in which the first curve peaks and the second curve takes off. This is another important weakness compared with typical Baillie Gifford core holdings, which often rest on a growth pole that is already visible today and likely to dominate the income statement in the future.

  There are three visible “second-curve candidates” today, but none has the scale to take over:

  • Agricultural biological solutions (rhizosphere microbes, biopesticides, soil improvement, water-saving solutions). The report gives this subsegment a CAGR of 11–15%, making it one of the fastest-growing areas and the best theoretical candidate for a “second curve.” But it is currently embedded in the Planetary Health division (whose FY2025 organic growth was only +6%, held back overall by mature detergent enzymes and biofuel enzymes). That shows agricultural biologics are not yet large enough to lift the whole division. They are still far from taking over.
  • Biosurfactants / bio-beauty (skin probiotics). The report gives CAGR 14–18%, the fastest growth rate, but also explicitly labels it “fast-growing but small-scale, and may only break through the ten billion scale over the next 5–10 years.” In other words, within five years it can at most move from negligible to worth mentioning. It cannot become the main engine after five years.
  • Microbiome interventions (gut microbiome, prebiotic + postbiotic). This has the greatest imagination space and is closest to “creating a new market,” but clinical validation and regulatory pathways are long, commercialization timing is hard to control, and even a quantifiable revenue line is difficult to provide today.

  What is truly contributing today and will keep contributing is an extension of the first curve, not a new curve. Feed enzymes (the company just bought out dsm-firmenich’s stake for EUR 1.5B, with closing in 2025-06) and rising probiotic penetration in emerging markets (2025 emerging-market organic growth of +9%) are about making existing businesses deeper and broader. They are not new engines.

  There is also a “negative curve” that must be offset as it fades. Biofuel enzymes account for about 4% of revenue and face structural headwinds. The report points to the 2026 phase-down of some U.S. biofuel subsidies under the OBBBA Act and fossil-fuel policy. That means the company not only lacks a powerful new engine; it must also use growth in other segments to offset decline in a mature business.

  The honest Baillie Gifford-style conclusion: If “does the second curve exist today?” is treated as a hard test, Novonesis’s answer is: “there are several seeds, but all are still in the nursery, and none can become the trunk within five years.” Its growth looks more like a slowly rising shrubland, with several business lines each contributing a few points, than the kind of new tree shooting upward that Baillie Gifford tends to prefer. For growth investors looking to underwrite a second curve, there is no clear target here.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Bottom line: the moat is deep and wide, the strongest part of the case. Its core is extremely high customer switching costs, oligopolistic scale in two arenas, and the industry’s largest strain library. Over the next three to five years it will probably stay stable and widen slightly, but it is already so wide that meaningful further widening is difficult. This is where Novonesis truly deserves the phrase “great company,” and it is the basic reason it can still be worth holding for the long term despite its modest growth. An independent third-party rating supports this: Morningstar gives Novonesis a “Wide Moat” rating and calls it the dominant global leader in enzymes and cultures.

  The four pillars of the moat, in order of importance:

  1. Customer switching costs, the hardest pillar. Once a strain or enzyme is written into a customer’s mass-production formula — Nestle yogurt, Henkel laundry detergent, Cargill feed — changing supplier requires 1–2 years of application validation plus regulatory filings. The report gives a customer repeat-purchase rate of >95% and a product repeat-purchase cycle of 5–15 years. This is not ordinary switching cost. It is lock-in measured in years and tied to regulatory approvals, and it is the basis for an EBITDA margin of 37%.

  2. Oligopolistic scale in two arenas, a structural advantage after the merger. After the 2024-01 merger of Novozymes and Chr. Hansen, Novonesis has close to 50% share in both industrial enzymes and microbial solutions, making it the clear number one. The report’s comparisons are industrial enzymes versus DSM-Firmenich at ~18%, and probiotics versus IFF at ~25%. Its scale is at least 2.5x the second player, creating economies of scale in procurement, R&D amortization, and a global network of 30+ factories.

  3. Strain library + patents, the hardest assets to replicate. A 750+ microbial strain IP library plus 6,000+ patents; the report calls it the industry’s largest library and No.1 in patent count, combined with continued investment of R&D/revenue of about 14%. A new entrant would need decades of fermentation accumulation to replicate this library. This is a true time moat.

  4. Regulatory barriers. ISO 22000 + FDA + EFSA + China GB multiple GMP certifications; building a new plant and obtaining certifications starts at 5–10 years.

  Will it widen or narrow over the next three to five years? Slightly wider, but with limited incremental room. Forces that widen it: ① competitors are busy with their own issues — DSM-Firmenich is still integrating after its 2023 merger, and IFF is still digesting its 2020 acquisition, giving Novonesis a window to gain share; ② the newly bought-out feed enzyme alliance stake further lifts feed enzyme share. Forces that narrow it, which the report honestly lists: ③ the rise of Chinese domestic industrial enzyme players (such as Vland) may erode share in the low-to-mid end; ④ market share near 50% is already ceiling-like, so there is naturally little room to widen the moat by taking more share. These forces offset each other. The net effect is that the moat remains extremely strong and widens slightly at the margin.

  The honest Baillie Gifford-style conclusion: On the question of whether the moat will widen or narrow, Novonesis gives the best answer in this case: a deep moat reinforced by merger and monetized through real profitability (37% EBITDA). The only reservation is that it is already close to its limit. The moat is more about being defensible than still being able to widen dramatically. That is materially different from the network-effect businesses Baillie Gifford prefers, where the moat strengthens exponentially with scale.

  Jun 10, 2026
• QIf its core business were disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Bottom line: Novonesis’s reinvention DNA is moderate rather than radical. It is good at evolving within the same technology paradigm and executing major integration moves (mergers, acquisitions, divestitures), but it has not yet gone through an existential test in which its core business was disrupted and it had to rebuild from the ground up. So this DNA has signs, but has not been stress-tested. Its approach to mistakes and bad news is relatively restrained and candid.

  First, consider the implicit premise of “can it reinvent itself when disrupted.” The evidence is indirect, not direct.

  • Positive evidence: the company itself is the result of an active paradigm recombination. The 2024-01 merger of Novozymes and Chr. Hansen into Novonesis reshaped two separate businesses, industrial enzymes and probiotics, into one platform. More importantly, cost synergies reached 100% run rate one year ahead of plan, showing that it has the execution muscle to land a major integration.
  • Positive evidence: it is willing to add and subtract in the portfolio. On one side, it bought out dsm-firmenich’s feed enzyme alliance stake for EUR 1.5B (completed in 2025-06); on the other, the 2025 annual-report framing clearly refers to “strategic exits”. Actively cutting businesses that are unprofitable or nonstrategic and moving resources toward higher-growth areas is healthy portfolio management.
  • Negative/untested evidence: there is no precedent of the core being disrupted. Its core — fermentation plus strain engineering — is exactly a beneficiary of the synthetic biology wave, not a target being disrupted by it. The truly disruptive threats in the report, such as Chinese domestic industrial enzymes, AI-accelerated strain discovery, and alternative proteins, are still early. The company has not yet been forced to prove whether it can be reborn after its main business is overturned. A more accurate description is that it is adaptable, but its anti-disruption ability is unproven in battle.

  Now consider how it handles mistakes and bad news: relatively candid, without glossing over them.

  • Most of the downside factors disclosed in the report — EUR/USD FX headwinds, Q1 2026 EBITDA margin of 37.8% slightly below 38.3% a year earlier, biofuel subsidy phase-down, and remaining integration costs — were proactively raised by the company in quarterly or annual disclosures. Management said in the annual report that it maintained guidance “despite currency headwinds”, without avoiding adverse items.
  • In governance, Novo Holdings’ 25.5% economic interest / 63.35% voting rights dual-class control and its long-term owner mindset mean management does not need to dress up quarterly numbers and can acknowledge short-term pain for long-term reasons. This is structurally positive for honestly handling bad news, though structurally weak for minority-shareholder voice, as discussed in the management question.

  The honest Baillie Gifford-style conclusion: Novonesis is a mature top student that actively evolves, can face bad news honestly, and is willing to add and subtract across the portfolio. These are all good genes. But the regenerative ability Baillie Gifford truly wants to see after a core business is disrupted has not yet had the chance, or the need, to prove itself. This deserves “good but not battle-tested,” neither overstating it as extremely resilient nor treating it as fragile simply because it has not suffered a crisis.

  Jun 10, 2026
• QDoes management, especially the founder, have a long-term view and deeply aligned interests with the company? Is it willing to sacrifice current profits for five to ten years from now?5/10

  A

  Bottom line: the long-term orientation is extremely strong, while interest alignment points in the right direction but lacks founder-style personal concentration. This is a company led by a long-term controlling shareholder (the Novo Foundation), with management incentives strongly tied to five-year performance. But it has no founder, and the CEO’s personal shareholding is very low. Alignment comes from institutions, not personal net worth. This is the typical governance picture for Novonesis: half excellent, half incomplete.

  Long-term orientation is the most prominent strength in this case, and it comes from the shareholder structure rather than an individual.

  • The controlling shareholder is Novo Holdings (wholly owned by the Novo Nordisk Foundation), with 25.5% economic ownership but 63.35% of voting rights. The core feature of a foundation-type major shareholder is that it does not demand short-term dividends or buybacks and can provide patient capital for long-term R&D and strategic M&A. This is exactly what gives Novonesis the confidence to sustain R&D/revenue of about 14%, execute a merger, and pursue a EUR 1.5B acquisition.
  • On whether it is willing to sacrifice current profits for five to ten years from now, the answer leans toward “yes”: during the integration period it allowed net debt/EBITDA to rise from 1.0× to 2.3×, and the report states that R&D was not cut during the merger to dress up short-term profit. These are actions that tolerate a less attractive near-term income statement in exchange for long-term position.

  Interest alignment points in the right direction, but lacks the founder-style “net-worth bet.”

  • Institutional alignment is in place: The report says about 80% of executive incentives are tied to 5-year TSR + EBITDA growth, rather than large U.S.-style stock-option dilution. 2025 equity-incentive/dividend discipline was also restrained (payout ratio of 58.4% of adjusted net profit, dividend DKK 4.25/share), and the company did not court the market by overextending the balance sheet.
  • Personal alignment is thin, the key weakness: There is no incumbent founder; the company was created by combining two century-old firms. CEO Ester Baiget’s personal shareholding is about 0.06% by the report’s framing. She is a professional manager, not an owner-operator who has put her net worth into the company. The founder/operator “same fate as the company” alignment that Baillie Gifford values most is missing here. Alignment rests more on the foundation shareholder’s long-termism and executive compensation contracts than on meaningful personal net-worth exposure.

  CEO background and execution are positives. Ester Baiget has served as Novozymes CEO since 2020-02 and continued as Novonesis CEO after the 2024 merger. She was previously president of Dow Industrial Solutions, and her five-year record is solid: revenue and margins have both risen during her tenure, and merger integration was completed ahead of schedule. She is a proven, execution-capable leader, but an excellent hired professional manager and a founder are two different kinds of alignment.

  The reservation for minority shareholders, which must be stated honestly: The dual-class structure lets Novo Holdings control 63.35% of voting rights with 25.5% economic ownership, leaving minority shareholders with limited governance influence. This is a double-edged sword: on one side, long-termism and resistance to short-term activist pressure; on the other, retail shareholders have almost no say over direction.

  The honest Baillie Gifford-style conclusion: On “long-term view + interest alignment,” Novonesis earns excellent institutional marks but misses the founder marks. It has the patient capital and long-term atmosphere Baillie Gifford values most, which is rare and genuinely positive. But it is not a founder-led company where the founder is heavily invested and fate is fully tied to minority shareholders. Alignment points in the right direction, but its strength is discounted by the absence of a founder, the CEO’s very low shareholding, and the dual-class structure. It should not be equated with a founder-driven growth stock.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth sustainable and not dependent on harming society or exploiting regulation?6/10

  A

  Bottom line: if Novonesis disappeared tomorrow, customers would miss it badly and could not replace it in the short term. This is a classic “indispensable inside the product” business. Its growth model does not harm society or rely on regulatory arbitrage; it is aligned with major sustainability trends such as reducing antibiotics, pesticides, and carbon. This is the cleanest part of the case. Novonesis scores highly on this question.

  How much customers would miss it: indispensability measured in years.

  • Novonesis’s strains and enzymes are written into customers’ mass-production formulas: Nestle/Danone fermented dairy, Henkel laundry detergent, and Cargill/ADM feed. If supply stopped tomorrow, customers could not simply switch supplier. They would need 1–2 years of application validation plus regulatory filings. The report gives a customer repeat-purchase rate of >95% and repeat-purchase cycles of 5–15 years. This embedded indispensability has real financial proof: it is what supports an adjusted EBITDA margin of 37.1% and a gross margin of about 59%. Customers pay that price because they cannot do without it.
  • The other side of indispensability is that the market structure leaves no obvious substitute. It holds close to 50% share in both industrial enzymes and microbial solutions. The second players, DSM-Firmenich and IFF, are less than half its size. In the short term, no other company in the industry can absorb the gap it would leave. Morningstar therefore gives it a Wide Moat rating and calls it the dominant leader in this market.

  Is growth sustainable and not dependent on harming society or regulation? It passes both tests and contributes positively.

  • Social dimension: the direction is solving problems, not creating externalities. Its core incremental growth comes precisely from sustainable needs: feed enzymes improve protein absorption and substitute for antibiotics, addressing antimicrobial resistance as a global public-health issue; agricultural biological solutions reduce chemical pesticide use and address climate change; industrial enzymes allow detergents to work at lower temperatures and with less water, reducing energy use. The larger this business becomes, the more positive the social externalities are. This is the opposite of businesses that grow through addiction, depletion, or regulatory arbitrage. The CEO’s inclusion among TIME100 Climate Leaders 2024 is reputational corroboration.
  • Regulatory dimension: regulation is its moat, not its liability. ISO 22000 + FDA + EFSA + China GB multiple certifications raise barriers for new entrants. It wins by meeting stricter regulation, not by evading regulation. This means tighter regulation is generally favorable to it by eliminating smaller players, rather than threatening it.

  Two honest reservations, neither changing the high-score conclusion:

  1. Regulation also has a cost side. The report notes that stricter EU REACH and U.S. FDA requirements can lengthen filing cycles for new strains/enzymes by 6–12 months and raise compliance costs. That slows growth, but it is not a stain of “harming society to grow.” The nature is different.
  2. Geopolitics is a real variable. U.S. 2025-12 restrictions on biotech investment into China, with China at about 10% of revenue, may weigh on the growth path. But this is also an external policy headwind, not evidence that the company’s own behavior is unsustainable.

  The honest Baillie Gifford-style conclusion: On the combined question of indispensability and sustainability, Novonesis is close to full marks. Customers cannot do without it for years at a time, the industry has no short-term substitute, and the bigger it grows, the more society benefits and the more regulation tends to support it. This is the quality that most withstands long-term ownership and the core reason ESG/sustainable investors would favor it.

  Jun 10, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate as it scales? Where does the money it earns go?7/10

  A

  Bottom line: unit economics are top-tier and improve with scale: about 59% gross margin, 37% EBITDA, strong free cash flow, and continuing efficiency gains after the merger. The money earned is mainly used for R&D, strategic M&A, and steady dividends. Capital allocation discipline is good. This is another strength for Novonesis. The quality of its unit economics deserves the phrase “high-quality business.”

  Gross margin and profitability: top-tier for specialized biotechnology.

  • FY2025 adjusted gross margin was about 59.1% (up +240bps YoY), and adjusted EBITDA margin was 37.1%. This is industry-leading in cross-section: the report compares GIVN at 24.2%, Symrise at ~21.5%, IFF at ~19%, and DSM-Firmenich at ~17%. Novonesis’s EBITDA margin is almost twice that of most peers. The root cause is the high switching cost, high value density, and long repeat-purchase cycles of strains and enzymes, which allow pricing power to reliably convert into profit.

  As it scales, unit economics are improving, with clear evidence.

  • The merger has produced real scale effects: FY2025 gross margin +240bps, EBITDA margin rising from about 35% before the merger to 37.1%, and management’s 2026 guidance looking further toward 37–38%. The improvement comes from shared fermentation infrastructure, procurement scale, amortization of R&D platforms, and cost synergies reaching 100% run rate one year ahead of plan. This is a positive scale curve where bigger means more profitable, not diseconomies of scale.
  • The report gives incremental return (ROIC) of 12–14%, solid but not spectacular. This needs to be stated honestly: large goodwill and intangible assets created by the merger lifted the invested-capital denominator, and the EUR 1.5B feed enzyme acquisition further dilutes ROIC. It sits in a “high-quality but not top-tier” range, unlike asset-light software that can generate 30%+ incremental returns.

  Where the money goes: three uses, with good discipline.

  1. R&D reinvestment, the first priority: R&D/revenue is about 14%, and was not cut during the merger to boost short-term profit, preserving the long-term lead in strain libraries and patents.
  2. Strategic M&A: EUR 1.5B to buy out dsm-firmenich’s feed enzyme alliance stake (completed in 2025-06), bringing distribution rights in-house and consolidating the No.1 position in feed enzymes.
  3. Steady dividends + deleveraging: 2025 dividend of DKK 4.25/share, payout ratio of 58.4% of adjusted net profit; at the same time, net debt/EBITDA fell back from 2.3× to about 1.9× after the merger-period spike. Capital allocation is restrained: no aggressive buybacks to support the share price, and no overextension of the balance sheet.

  Free cash flow quality is high. FY2025 pre-acquisition free cash flow was about EUR 770M, equal to 19% of sales. The report’s framing puts free cash flow at about 62% of adjusted EBITDA and about 105% of net profit. Profits convert into real cash; this is not a case of paper earnings with missing cash flow.

  The honest Baillie Gifford-style conclusion: Unit economics are Novonesis’s most stable foundation: high gross margin, high EBITDA, further efficiency gains with scale, solid cash flow, and disciplined capital allocation. The only aspect that is not “Baillie Gifford spectacular” is the 12–14% incremental return (ROIC), which is high-quality rather than top-tier because merger goodwill, asset-heavy fermentation, and M&A dilute the denominator. But as a business that knows where its money goes and becomes more profitable as it scales, this item is high quality.

  Jun 10, 2026
• QWhat conditions would have to hold at the same time for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today’s share price?2/10

  A

  Bottom line: a fivefold rise in ten years (about 17.5% annualized) requires multiple demanding conditions to hold simultaneously. The most important one, revenue acceleration, conflicts with the company’s mid-speed DNA, so realism is low. At the same time, today’s share price is not cheap. On true trailing earnings it is actually expensive, already paying for a flawless merger outcome and leaving limited asymmetric upside.

  What conditions must hold for a fivefold rise in ten years, and why they are unrealistic. A 5 times share price ≈ earnings growth × valuation change. Broken down:

  • Condition one: earnings must compound at least 14–17%/year (volume and price both rising, margins reaching the top, and M&A staying accretive). This is the hardest condition and almost impossible. Management’s own long-term target is only organic +6–8%. Even adding margin expansion (roughly 37%→40%) and occasional M&A, the optimistic outcome is only mid-teens earnings growth, still far short of 14–17% on a sustained basis. To close the gap, agricultural biologics/microbiome/bio-beauty would have to suddenly scale, even though the report itself says these businesses “may only reach scale over the next 5–10 years.”
  • Condition two: valuation must not contract, and ideally should expand. But current valuation is already high, as discussed below. If the company is classified ten years from now as a mature low-growth stock, PE is more likely to contract than expand. That would subtract from the 5 times outcome rather than add to it.
  • Condition three: FX must stop being a structural headwind, integration must not backslide, and China share must not be eroded by domestic substitutes. These are defensive “nothing goes wrong” items. They can prevent downside, but they do not create upside power.

  All four conditions would need to be hit and sustained for ten years. That is not realistic. This is not a high-odds lottery ticket that might pay off; structurally, the target is out of reach.

  What today’s share price implies: priced for the perfect script, and expensive on real earnings.

  • True trailing valuation is not cheap. As of 2026-06-09, the B share was about DKK 383.6, market cap about DKK 178.7B, trailing EPS only DKK 9.56, implying trailing PE of about 40 times. This matters: the report’s text saying “TTM PE about 26.5x / EPS DKK 13.8” does not match primary data. True trailing GAAP earnings are dragged down by amortization of intangibles created by the merger, and trailing PE is actually close to 40 times, far more expensive than the report implies. Even on an ex-amortization basis, 2026 forward PE is about 23.5 times. For a mid-speed compounder with +6–8% long-term growth and about 1.8% dividend yield, this is a quality premium, not cheapness.
  • The embedded expectation is “perfect merger + perpetual synergies + no growth slowdown.” The current price already includes early realization of cost synergies, smooth Feed Enzyme integration, and margins holding at 37–38%. That means even if the company delivers on what it has promised, the share price may not have much upside. If growth falls to the low end of guidance or FX headwinds persist, valuation faces downside pressure toward a mature-stock PE of 16–18x. The report’s own pre-mortem also lists this as the biggest risk, with probability around 25%.

  The honest Baillie Gifford-style conclusion: “Fivefold in ten years” is a structurally unanswerable question for Novonesis. The key condition, earnings acceleration, conflicts with its mid-speed DNA, while the share price has already paid for perfect execution (true trailing PE about 40x, forward about 23.5x). It is more likely to be a steady “roughly 1.4–2 times over ten years, helped by compounding and dividends” holding than an explosive Baillie Gifford-style growth stock. Buying today earns the time value of a quality business, not a rerating from market misperception. The latter is almost absent today.

  Jun 10, 2026
• QWhy has the market not realized all this yet? Is it because investors do not understand it, look down on it, or cannot look far enough? What would become the “narrative inflection point”?3/10

  A

  Bottom line: the market actually understands this quite well. This is not a mispriced or overlooked perception-gap stock. It is a high-quality leader that is well researched and reasonably, even richly, priced. If there is anything the market has “not realized,” it is more likely underestimating the medium-term persistence of FX headwinds, a negative expectation gap, rather than missing a hidden upside story. The honest answer for Novonesis is precisely that there is no obvious perception-gap dividend.

  First, reject the three classic perception gaps: “not understood,” “looked down on,” and “not viewed far enough out.” Most do not apply.

  • “Not understood” does not apply. This company is well covered by sell-side and independent research: Morningstar has a detailed Wide Moat report and describes it as the dominant global leader in enzymes and cultures. Market share, moat, and merger synergies are all public consensus. The business model is B2B and unknown to consumers, but professional investors know it well. It is not hidden in a corner without coverage.
  • “Looked down on” does not apply; the opposite is true, the market gives it a premium. As of 2026-06-09, the B share was about DKK 383.6, trailing PE about 40 times, 2026 forward PE about 23.5 times, and dividend yield about 1.8%. For a company with +6–8% long-term growth, this is a quality-premium valuation. It shows that the market not only does not look down on it, but fully recognizes its moat and certainty. Note that the report’s “TTM PE about 26.5x” understates the true expensiveness; trailing GAAP PE is actually near 40x.
  • “Not viewed far enough out” also mostly does not apply. Merger synergies were achieved one year early, and the Feed Enzyme EUR 1.5B acquisition had already closed in 2025-06. These positives are public facts and already reflected in the share price, not future value the market has yet to see.

  If one must identify something the market may not have fully priced, the direction is negative, not positive. The real underpriced item may be risk rather than opportunity: ① how persistent EUR/USD strength will be in eroding the bridge from organic growth to reported revenue, and for how many years. If this exceeds expectations, Novonesis could be rerated from a mid-speed growth stock to a mature low-growth stock, with PE reverting toward 16–18x; ② the long-term share erosion from the rise of Chinese domestic industrial enzymes. The premium currently assigned by the market looks more like an assumption that these headwinds are temporary. If that is disproven, the expectation gap opens downward.

  What would become the “narrative inflection point”? Both directions exist, but disappointment is more likely than surprise.

  • Upside inflection point, harder to trigger: one of agricultural biologics, bio-beauty, or microbiome unexpectedly scales, pushing group organic growth from 6–7% into double digits and convincing the market that a second curve has taken off. But the report judges that these segments are unlikely to become material within five years, so the trigger probability is low.
  • Downside inflection point, more important to watch: Q2/Q3 2026 EBITDA margin failing to hold 37%, organic growth falling to the low end of guidance (+5%), or FX headwinds continuing. Any of these could trigger a mature-stock rerating and undermine the current valuation of about 40x trailing / 23.5x forward. The report’s pre-mortem lists “FX headwinds + slower growth” as the highest-probability downside path (~25%), consistent with this view.

  The honest Baillie Gifford-style conclusion: The core Baillie Gifford question of “why has the market not realized this yet?” is almost invalid for Novonesis. The market understands it, respects it, looks far enough out, and assigns it the quality premium it deserves. There is no overlooked positive perception gap to capture here. The more realistic inflection point is a downside rerating triggered by earnings or FX disappointment. For investors trying to find a great growth stock the market has not yet understood, Novonesis is a good company whose answer is already written on its face. What it lacks is the unpriced growth story.

  Jun 10, 2026